- Home
- BGR vs RIGL Comparison
BGR vs RIGL Comparison
Compare BGR & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGR
- RIGL
- Stock Information
- Founded
- BGR 2004
- RIGL 1996
- Country
- BGR United States
- RIGL United States
- Employees
- BGR N/A
- RIGL N/A
- Industry
- BGR Trusts Except Educational Religious and Charitable
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- BGR Finance
- RIGL Health Care
- Exchange
- BGR Nasdaq
- RIGL Nasdaq
- Market Cap
- BGR 350.6M
- RIGL 335.5M
- IPO Year
- BGR N/A
- RIGL 2000
- Fundamental
- Price
- BGR $13.59
- RIGL $38.85
- Analyst Decision
- BGR
- RIGL Buy
- Analyst Count
- BGR 0
- RIGL 5
- Target Price
- BGR N/A
- RIGL $38.20
- AVG Volume (30 Days)
- BGR 73.3K
- RIGL 995.6K
- Earning Date
- BGR 01-01-0001
- RIGL 08-05-2025
- Dividend Yield
- BGR 6.02%
- RIGL N/A
- EPS Growth
- BGR N/A
- RIGL N/A
- EPS
- BGR 0.69
- RIGL 5.43
- Revenue
- BGR N/A
- RIGL $267,921,000.00
- Revenue This Year
- BGR N/A
- RIGL $59.93
- Revenue Next Year
- BGR N/A
- RIGL N/A
- P/E Ratio
- BGR $18.97
- RIGL $7.15
- Revenue Growth
- BGR N/A
- RIGL 105.62
- 52 Week Low
- BGR $11.38
- RIGL $12.66
- 52 Week High
- BGR $13.37
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- BGR 63.47
- RIGL 68.57
- Support Level
- BGR $13.18
- RIGL $39.00
- Resistance Level
- BGR $13.31
- RIGL $42.08
- Average True Range (ATR)
- BGR 0.14
- RIGL 2.32
- MACD
- BGR 0.03
- RIGL -0.37
- Stochastic Oscillator
- BGR 82.10
- RIGL 53.26
About BGR BlackRock Energy and Resources Trust
BlackRock Energy & Resources Trust is a closed-end equity fund providing total return through a combination of current income, gains and capital appreciation by investing in equity securities and derivatives of energy and natural resources companies. The fund invests in various sectors such as information technology, financials, healthcare, consumer discretionary, industrial, energy, materials and utilities.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.